Search

Displaying results 1671 - 1680 of 3600 in total
  1. Drug

    Mevidalen

    go.drugbank.com/drugs/DB19034
    Investigational

    Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or

  2. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Mixtures: Isolyte P in Dextrose, ISOLYTE-P PVC 250 ML(SETLI)
  3. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous

  4. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbe...

  5. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  6. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    Dasiglucagon

    go.drugbank.com/drugs/DB15226
    Approved

    It is characterized by neurological impairment, with manifestations like loss of consciousness and seizure.

    Categories: Glucagon Receptor Agonists
  8. Drug

    Itruvone

    go.drugbank.com/drugs/DB21543
    Investigational

    Itruvone is under investigation in clinical trial NCT02322086 (A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10).

  9. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Congenital loss or deficiency of Factor VIII results in the physiologic impairment of the coagulation clotting cascade, and as a result, leads to easy bruising and bleeding. … Replacement of Factor VIII is essential for the treatment of Hemophilia A, which is caused by mutations in the Factor VIII gene, leading to a functional deficiency or complete loss of protein.

    Mixtures: Monoclate-P, Humate-PProducts: Monoclate-P, Haemate P 250 I.E. FVIII / 600 I.E. VWF Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung. Haemate P 500 I.E. FVIII / 1200 I.E.
  10. Drug

    MVR-T3011

    go.drugbank.com/drugs/DB17378
    Investigational

    MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1